Omega-3 Fatty Acids and Insulin Sensitivity

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 21, 2012

Primary Completion Date

October 30, 2014

Study Completion Date

June 8, 2015

Conditions
Insulin Resistance
Interventions
DRUG

Omega-3

Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.

DRUG

placebo

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Building Interdisciplinary Research Careers in Women's Health

UNKNOWN

lead

Mayo Clinic

OTHER